TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05344521

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integra®
Description: A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra®-SC
Description: A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
Study: NCT06494137

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inulin
Description: inulin from chicory root

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: inulin from chicory root

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: inulin from chicory root
Study: NCT04829435

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Study: NCT05225402

Intervention type: DRUG
Intervention: Hemodynamic measurements during reduction in Norepinephrine and fluid boli.
Description: 1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV\>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP.
Study: NCT04733690

Intervention type: DIETARY_SUPPLEMENT
Intervention: Common bean product
Description: Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected

Intervention type: DIETARY_SUPPLEMENT
Intervention: Common bean product
Description: Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected

Intervention type: DIETARY_SUPPLEMENT
Intervention: Common bean product
Description: Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected
Study: NCT06199388

Intervention type: OTHER
Intervention: Survival state
Description: We recorded clinically relevant information and survival status of pediatric glioma patients

Intervention type: OTHER
Intervention: Survival state
Description: We recorded clinically relevant information and survival status of pediatric glioma patients
Study: NCT05841823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRET)
Description: The relaxation scene includes four beautiful landscapes, and patients can choose any of these four, as perceived to be the most comfortable landscape. The visual stimulation of high-risk scene is designed as any combination of four different scenes (street barbecue stands, restaurant, bar and home) and four kinds of alcoholic beverages (Chinese liquor, beer, grape wine and cocktail), which are customized according to the patient's personal preference. At the same time, the odor of the alcoholic beverage of the patient's choice will be provided as an olfactory stimulation. The aversive situation will be the visual and auditory stimulation provided by a video of an alcoholic vomiting, while olfactory stimulation will be provided by cotton balls soaked in fermented dairy products.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy (ACT)
Description: The initial session began with case formulation. Subsequent sessions involved learning on acceptance and acknowledgement of unpleasant thoughts and feelings associated with alcohol craving and clinical features of alcohol use disorder, cognitive defusion on how to dissociate self avoidance of unpleasant thoughts and feelings, learning and practicing mindfulness exercise (such as mindfulness breathing) to make self aware of the many things that occurred presently which can be enjoyed and focus on rather than focusing on unpleasant thoughts and feelings, and learning to be aware of the safe self which is separated from the unpleasant thoughts and feelings and identifying values in life and strategies to achieve these values (therapeutic processes in hexaflex).
Study: NCT05956795

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Sonographic imaging will be performed of lymph node basins

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Sonographic imaging will be performed of lymph node basins

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Sonographic imaging will be performed of lymph node basins
Study: NCT04807348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar 32mg
Description: Administrated once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar 48mg
Description: Administrated once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Chiglitazar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: most tolerable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: most tolerable dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Hydrochloride
Description: most tolerable dose
Study: NCT05721235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Description: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Study: NCT05858619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: dupilumab 600 mg injection initially and then 300 mg every other week
Study: NCT05758259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination oral and topical vitamin D
Description: combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral placebo and topical cholecalciferol
Description: oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo and basic ingredient placebo topical vitamin D
Description: oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
Study: NCT06203561

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT05870943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Argon Plasma Coagulation
Description: Hybrid APC will be utilized to first ablate the gastric mucosa along the greater curve of the stomach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Sleeve Gastroplasty
Description: Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty
Description: Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
Study: NCT04901689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab
Description: Leronlimab 700 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06140030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Mindfulness-training mobile health application
Study: NCT05744804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: -group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg
Description: receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)
Description: control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
Study: NCT04401683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation with a digital biofeedback system
Description: Participants in the experimental group will perform a 12-week digital exercise program, to be performed independently at home using the SWORD Phoenix® medical device, under remote monitoring from a physical therapist.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional home-based rehabilitation
Description: Participants in the control group will benefit from a 12-week home-based rehabilitation program, consisting of 12 face-to-face sessions (1 per week) with a physical therapist, complemented by additional non-supervised sessions. Both supervised and unsupervised sessions will follow the same set of exercises defined for the experimental group.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises.
Study: NCT05282134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet cupping therapy
Description: Wet cupping therapy is a bloodletting application done by cups on the skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a complementary application of TCM done by needles
Study: NCT06259656

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
Description: Maternal blood and cord blood were collected to test for COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
Study: NCT05721599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care with nutrition and lifestyle counselling
Description: The structured care includes specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group and case management.
Study: NCT05242198

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic prostatectomy
Description: patients who will undergo robotic prostatectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic prostatectomy
Description: patients who will undergo robotic prostatectomy
Study: NCT05829369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrinsic foot muscle strengthening exercises
Description: participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal footwear with prescribed walking
Description: Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
Study: NCT06197919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural exercises
Description: In this study forward head posture will be defined as CVA\<49°, which was diagnosed by photogrammetry method.~The postural exercise program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Kendall et al's approach. The exercises involved~1. chin tucks ins~2. a chin drop in sitting~3. shoulder retraction~4. unilateral and bilateral pectoralis stretches Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each. This program was to be repeated 4 times per week. They also returned for a consultation every 2 weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12 repetitions, 3 times easily with correct form

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural exercises with breathing exercises
Description: The postural exercise program consisted the exercises i.e chin tucks in, a chin drop in sitting, shoulder retraction. Participants were instructed to complete 3sets of 12repetitions of these exercises. This program was to be repeated 4times per week. They also returned for a consultation every 2weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12repetitions, 3times easily with correct form.~For the breathing exercises in experimental group, breathing program includes respiratory muscle training, relaxation techniques, breathing techniques, e.g., deep breathing, hand controlled diaphragmatic breathing, relaxation technique, deep breathing, controlled diaphragmatic breathing, slow relaxed exhalation with pursed lips technique, and segmental breathing techniques. exercise protocol will be continued for 6 weeks with and initial, after 3weeks and final assessment of pain and CVA.
Study: NCT06164990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEKK framework
Description: PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept
Study: NCT04854837

Intervention type: DRUG
Intervention: Remdesivir
Description: Remdesivir treatment
Study: NCT05318391

Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression profile
Description: Diagnostic Test:~The Canhelp-COO Assay (Canhelp Genomics CO., Ltd) for differentiating COO subtypes using gene expression analysis by real-time PCR (RT-PCR)
Study: NCT06128460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240mg, q3w，8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: cisplatin 40mg/m2 for 5-6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 45-50Gy/1.8Gy/25-28f
Study: NCT05518747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: In this group participants will receive probiotic supplements twice a day (morning and evening) for a period of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this group participants will receive placebo twice a day (morning and evening) for at period of 12 weeks.
Study: NCT05430633

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Appendectomy - laparoscopic or open

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Appendectomy - laparoscopic or open
Study: NCT06206759

Intervention type: DRUG
Intervention: administration of vitamin C
Description: administration of vitamin C to ICU patients
Study: NCT05383027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening Control (MLC)
Description: MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Focused Breathing
Description: Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
Study: NCT05533983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation with Nivolumab
Description: This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
Study: NCT05920876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS32015
Description: Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
Study: NCT04952064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside GM1
Description: Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside GM1
Description: Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Study: NCT06329583

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: diaphragmatic breathing
Description: Different positions and techniques for diaphragmatic breathing
Study: NCT05988801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant
Description: glass ionomer-based sealant material
Study: NCT06327841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sesame oil
Description: 15min of oil pulling with 15ml sesame oil for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: distilled water
Description: 15min rinsing with 15ml distilled water for 8 weeks